295 related articles for article (PubMed ID: 32120043)
1. Treatment of hepatitis D: an unmet medical need.
Caviglia GP; Rizzetto M
Clin Microbiol Infect; 2020 Jul; 26(7):824-827. PubMed ID: 32120043
[TBL] [Abstract][Full Text] [Related]
2. Investigational drugs in development for Hepatitis D.
Rizzetto M
Expert Opin Investig Drugs; 2017 Sep; 26(9):999-1005. PubMed ID: 28730878
[TBL] [Abstract][Full Text] [Related]
3. Targeting Hepatitis D.
Rizzetto M
Semin Liver Dis; 2018 Feb; 38(1):66-72. PubMed ID: 29471567
[TBL] [Abstract][Full Text] [Related]
4. Hepatitis delta virus: insights into a peculiar pathogen and novel treatment options.
Lempp FA; Ni Y; Urban S
Nat Rev Gastroenterol Hepatol; 2016 Oct; 13(10):580-9. PubMed ID: 27534692
[TBL] [Abstract][Full Text] [Related]
5. Chronic Hepatitis D; at a Standstill?
Rizzetto M
Dig Dis; 2016; 34(4):303-7. PubMed ID: 27170382
[TBL] [Abstract][Full Text] [Related]
6. Emerging concepts for the treatment of hepatitis delta.
Elazar M; Glenn JS
Curr Opin Virol; 2017 Jun; 24():55-59. PubMed ID: 28475945
[TBL] [Abstract][Full Text] [Related]
7. Persistent Control of Hepatitis B Virus and Hepatitis Delta Virus Infection Following REP 2139-Ca and Pegylated Interferon Therapy in Chronic Hepatitis B Virus/Hepatitis Delta Virus Coinfection.
Bazinet M; Pântea V; Cebotarescu V; Cojuhari L; Jimbei P; Anderson M; Gersch J; Holzmayer V; Elsner C; Krawczyk A; Kuhns MC; Cloherty G; Dittmer U; Vaillant A
Hepatol Commun; 2021 Feb; 5(2):189-202. PubMed ID: 33553968
[TBL] [Abstract][Full Text] [Related]
8. New treatment options for delta virus: Is a cure in sight?
Yurdaydin C
J Viral Hepat; 2019 Jun; 26(6):618-626. PubMed ID: 30771261
[TBL] [Abstract][Full Text] [Related]
9. Beyond Pegylated Interferon-Alpha: New Treatments for Hepatitis Delta.
Deterding K; Wedemeyer H
AIDS Rev; 2019; 21(3):126-134. PubMed ID: 31532397
[TBL] [Abstract][Full Text] [Related]
10. Safety and efficacy of REP 2139 and pegylated interferon alfa-2a for treatment-naive patients with chronic hepatitis B virus and hepatitis D virus co-infection (REP 301 and REP 301-LTF): a non-randomised, open-label, phase 2 trial.
Bazinet M; Pântea V; Cebotarescu V; Cojuhari L; Jimbei P; Albrecht J; Schmid P; Le Gal F; Gordien E; Krawczyk A; Mijočević H; Karimzadeh H; Roggendorf M; Vaillant A
Lancet Gastroenterol Hepatol; 2017 Dec; 2(12):877-889. PubMed ID: 28964701
[TBL] [Abstract][Full Text] [Related]
11. Preclinical assessment of antiviral combination therapy in a genetically humanized mouse model for hepatitis delta virus infection.
Winer BY; Shirvani-Dastgerdi E; Bram Y; Sellau J; Low BE; Johnson H; Huang T; Hrebikova G; Heller B; Sharon Y; Giersch K; Gerges S; Seneca K; Pais MA; Frankel AS; Chiriboga L; Cullen J; Nahass RG; Lutgehetmann M; Toettcher JE; Wiles MV; Schwartz RE; Ploss A
Sci Transl Med; 2018 Jun; 10(447):. PubMed ID: 29950446
[TBL] [Abstract][Full Text] [Related]
12. HBV/HDV Coinfection: A Challenge for Therapeutics.
Koh C; Da BL; Glenn JS
Clin Liver Dis; 2019 Aug; 23(3):557-572. PubMed ID: 31266627
[TBL] [Abstract][Full Text] [Related]
13. Hepatitis delta and HIV infection.
Soriano V; Sherman KE; Barreiro P
AIDS; 2017 Apr; 31(7):875-884. PubMed ID: 28121714
[TBL] [Abstract][Full Text] [Related]
14. Understanding early serum hepatitis D virus and hepatitis B surface antigen kinetics during pegylated interferon-alpha therapy via mathematical modeling.
Guedj J; Rotman Y; Cotler SJ; Koh C; Schmid P; Albrecht J; Haynes-Williams V; Liang TJ; Hoofnagle JH; Heller T; Dahari H
Hepatology; 2014 Dec; 60(6):1902-10. PubMed ID: 25098971
[TBL] [Abstract][Full Text] [Related]
15. What is the Path Forward to Treat Hepatitis Delta Virus?: Old Treatments and New Options.
Asselah T
Clin Liver Dis; 2023 Nov; 27(4):985-995. PubMed ID: 37778781
[TBL] [Abstract][Full Text] [Related]
16. REP 2139: Antiviral Mechanisms and Applications in Achieving Functional Control of HBV and HDV Infection.
Vaillant A
ACS Infect Dis; 2019 May; 5(5):675-687. PubMed ID: 30199230
[TBL] [Abstract][Full Text] [Related]
17. Optimizing lonafarnib treatment for the management of chronic delta hepatitis: The LOWR HDV-1 study.
Yurdaydin C; Keskin O; Kalkan Ç; Karakaya F; Çalişkan A; Karatayli E; Karatayli S; Bozdayi AM; Koh C; Heller T; Idilman R; Glenn JS
Hepatology; 2018 Apr; 67(4):1224-1236. PubMed ID: 29152762
[TBL] [Abstract][Full Text] [Related]
18. Nucleic Acid Polymers Are Active against Hepatitis Delta Virus Infection
Beilstein F; Blanchet M; Vaillant A; Sureau C
J Virol; 2018 Feb; 92(4):. PubMed ID: 29212929
[TBL] [Abstract][Full Text] [Related]
19. Quantitative analysis of hepatitis D virus RNA and hepatitis B surface antigen serum levels in chronic delta hepatitis improves treatment monitoring.
Manesis EK; Schina M; Le Gal F; Agelopoulou O; Papaioannou C; Kalligeros C; Arseniou V; Manolakopoulos S; Hadziyannis ES; Gault E; Koskinas J; Papatheodoridis G; Archimandritis AJ
Antivir Ther; 2007; 12(3):381-8. PubMed ID: 17591028
[TBL] [Abstract][Full Text] [Related]
20. [Bulevirtide as the first specific agent against hepatitis D virus infections-mechanism and clinical effect].
Nkongolo S; Hollnberger J; Urban S
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2022 Feb; 65(2):254-263. PubMed ID: 35028672
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
